just ask yourself....
Do you think they would re-align priorities and specifically make ALLSTROM a key strategic focus if the forthcoming data wasnt compelling ?
Allstrom : The Mother of all Fibrotic Diseases
This comes right back to the statements at the KOL by the very reputable third party clinicians and doctors.... 4050 not only halts but actually appears to reverse fibrosis. Layer that in with the MOA Peer review and you can start to see what Wall street is seeing.
Now this all comes down to exactly when they turn the key on becoming a Nasdaq listed company... and watch the IP value be finally appreciated for what it is.